Rivaroxaban Koanaa

Rivaroxaban Koanaa is an anticoagulant medicine (a medicine that prevents blood clotting) used: - to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (a clot in a blood vessel supplying the lungs), and to prevent DVT and pulmonary embolism from recurring in adults; - to prevent venous thromboembolism (VTE, the formation of blood clots in the veins) in adults who are undergoing surgery to replace a hip or knee; - to treat VTE and prevent VTE from recurring in children and adolescents aged less than 18 years; - to prevent stroke (caused by a blood clot in the brain) and systemic embolism (a blood clot in another organ) in adults with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart). Rivaroxaban Koanaa contains the active substance rivaroxaban and is a ‘generic medicine’. This means that Rivaroxaban Koanaa contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Rivaroxaban Koanaa is Xarelto. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf).